Skip to main content

Elsbernd Brian's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Nov 15, 2022

Accession no.
0001161697-22-000549
Filed
Nov 15, 2022
Trade date
Nov 11-14, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $238.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Elsbernd BrianCIK 0001763511Officer (Chief Compliance/Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 11, 2022Common stock, par value $0.001 per shareSSaleDisposed−14,666$16.24−$238,175.8411,096Direct
Nov 14, 2022Common stock, par value $0.001 per shareMOption exerciseAcquired+65,000$1.85+$120,25076,096Direct
Nov 14, 2022Common stock, par value $0.001 per shareMOption exerciseAcquired+40,000$0.79+$31,600116,096Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 14, 2022Common StockMOption exerciseDisposed−65,000$0.00$0885,667Direct
Nov 14, 2022Common StockMOption exerciseDisposed−40,000$0.00$0845,667Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)